We developed a new tool that can identify open reading frames (ORFs) for a given transcript and reconstruct protein isoforms using RNA-Seq data. Moreover, we use a modified version of the measure of abundance Fragments Per Kilobase of transcript per Million mapped reads (FPKM), aka adaptive FPKM (AFPKM), which in addition to using information about the length of the transcript, it takes into the account the actual length of the ORF. Using this new expression measure, we were able to identify 10 protein isoforms that were differentially expressed in stage 2 versus further stages of prostate cancer. Using identified protein isoforms, we were able to obtain more than 97% accuracy for discriminating stage 2 from subsequent stages of prostate cancer.
INTRODUCTION
Protein synthesis is the process of transforming transcripts into amino acid chains. Formation of a polypeptide chain occurs by translating the actual ORF, Finding ORFs corresponding to a given mRNA transcript is a vital step in reconstructing protein isoforms, which leads to better understanding of RNA alternative splicing and its effects in diseases like cancer.
We propose a model that integrates RNA-Seq data with machine learning techniques and uses protein isoforms as features for prediction of cancer progression. Our scheme explores the characteristics of RNA-Seq by inferring protein isoforms from transcripts. The model delivers a handful of relevant biomarkers that can be used at the protein level and open new avenues toward better understanding of progression in prostate cancer.
MATERIALS AND METHODS
We have developed a tool for finding protein isoforms, in all six frames corresponding to a given mRNA sequence and identifying the actual ORF from RNA-Seq data. The dataset we used is Long's dataset with NCBI GEO accession no. GSE54460, which contains 106 samples from 100 patients [3] . The samples were grouped according to their stage/sub-stage; In this study, we are interested in discriminating between stage 2 and subsequent stages of prostate cancer progression. Stages T 3 ; T 3A ; T 3B and T 4 were merged into a new group named T 3,4 . Our experiment involved 47 samples (30 and 17 samples for stages T 2C and T 3,4 , respectively). The genes transcripts for those samples were reconstructed in previous work [4] , and that resulted in 33,801 coding RNA transcripts (features) for different stages.
We fed our tool [1] with those transcripts to find the actual ORFs in each of them and use the ratio between the length of ORFs and transcripts to normalize the FPKM values. First, all the six reading frames for the 5' ! 3' and 3' ! 5' strands are generated by assigning the corresponding amino acids to each codon. Then, the longest stretch of the ORF presents in these six frames is selected as the actual ORF. If l(tr) is length of a given transcript and l(ORF) is the length of its ORF, then:
Adaptive FPKM (AFPKM) takes into the account the amount of transcript that is actually translated into protein.
Feature Selection
With 33,801 transcripts or features, it is important to apply feature selection in order to reduce the dimensionality problem and improve the classification performance. For this purpose, we used a wrapper approach based on the minimum Redundancy Maximum Relevance (mRMR) feature selection method.
EXPERIMENTAL RESULTS
Our method identified 10 protein isoforms expressed differentially between stage 2 and subsequent stages of prostate cancer. Table 1 shows identified transcripts for discriminating stages T 2C and T 3, 4 of prostate cancer. Figure 1 shows the performance of different classifiers using the selected protein isoforms. As shown in the figure, the Nave Bayes classifier outperformed the other classifiers by predicting almost all the samples correctly (only one sample was misclassified). In general, the results illustrate that the selected transcripts are able to differentiate samples across stages T 2C and further stages of prostate cancer with a high level of accuracy and can be investigated more as potential biomarkers of prostate cancer progression. Figure 2 represents the expression trend level of the chosen isoforms across stages T 2C and T 3, 4 . Transcript NM_001099285, in particular, had a significant FPKM variation between T 2C and T 3, 4 . Prothymosin (PTMA) is a nuclear oncoprotein transcription factor that is essential for cell cycle progression and proliferation [2] . It has been shown that changes in PTMA (corresponding gene to transcript NM_001099285) expression is involved in development and progression of prostate cancer [5] . In all of our samples, we experienced a sudden increase in expression of PTMA as the tumor progresses across later stages. This makes that transcript a potential biomarker for prostate cancer progression between stage 2 and subsequent stages, and worth more investigation. 
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